1. Home
  2. RETO vs SKYE Comparison

RETO vs SKYE Comparison

Compare RETO & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RETO

ReTo Eco-Solutions Inc.

N/A

Current Price

$0.55

Market Cap

5.5M

ML Signal

N/A

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

N/A

Current Price

$1.37

Market Cap

6.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RETO
SKYE
Founded
1999
2012
Country
China
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5M
6.4M
IPO Year
2016
2013

Fundamental Metrics

Financial Performance
Metric
RETO
SKYE
Price
$0.55
$1.37
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $68.00
AVG Volume (30 Days)
★ 1.8M
20.7K
Earning Date
11-10-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.09
$0.26
52 Week High
$7.84
$12.80

Technical Indicators

Market Signals
Indicator
RETO
SKYE
Relative Strength Index (RSI) 43.45 33.54
Support Level $0.54 $0.26
Resistance Level $0.68 $1.66
Average True Range (ATR) 0.11 0.12
MACD -0.03 -0.01
Stochastic Oscillator 0.66 7.32

Price Performance

Historical Comparison
RETO
SKYE

About RETO ReTo Eco-Solutions Inc.

ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation, and construction of urban ecological environments for capturing, controlling, and reusing rainwater. It operates through two segments, namely Equipment and technical service segment, and Craft beer segment. The company earns its revenue from the Equipment and technical service segment. Geographically, it derives a majority of its revenue from China.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: